{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:56:44Z","timestamp":1781351804256,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.7759\/cureus.110774","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:18:19Z","timestamp":1781349499000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations"],"prefix":"10.7759","author":[{"given":"Suhail","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfarooq","family":"Alshaikhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niket","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Nepal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Kenmoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Bayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Shrotriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020, 383:617-29. 10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-635060","article-title":"How I treat acute myeloid leukemia presenting with preexisting comorbidities","volume":"128","author":"Ofran Y","year":"2016","unstructured":"Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016, 128:488-96. 10.1182\/blood-2016-01-635060","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz KW","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, et al.. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024, 99:615-24. 10.1002\/ajh.27246","journal-title":"Am J Hematol"},{"key":"ref4","unstructured":"Acute myeloid leukemia. (2025). Accessed. May 25, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000382","article-title":"Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis","volume":"27","author":"Krashin E","year":"2016","unstructured":"Krashin E, Dolberg OJ, Hellmann I, Huitema AD, Rosing H, Ellis M. Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis. Anticancer Drugs. 2016, 27:800-3. 10.1097\/CAD.0000000000000382","journal-title":"Anticancer Drugs"},{"key":"ref6","unstructured":"Venclexta. (2026). Accessed. May 25, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/208573s031lbl.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15935","article-title":"Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis","volume":"90","author":"Noorani B","year":"2024","unstructured":"Noorani B, Menon RM, Chen X, et al.. Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis. Br J Clin Pharmacol. 2024, 90:748-58. 10.1111\/bcp.15935","journal-title":"Br J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis","volume":"18","author":"Jones AK","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016, 18:1192-202. 10.1208\/s12248-016-9927-9","journal-title":"AAPS J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2248","article-title":"Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials","volume":"63","author":"Gong JQ","year":"2023","unstructured":"Gong JQ, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH. Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol. 2023, 63:950-60. 10.1002\/jcph.2248","journal-title":"J Clin Pharmacol"},{"key":"ref10","unstructured":"Onureg. (2026). Accessed. May 25, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/214120s003lbl.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701646","article-title":"Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease","volume":"23","author":"Perry JJ","year":"1999","unstructured":"Perry JJ, Fleming RA, Rocco MV, et al.. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant. 1999, 23:839-42. 10.1038\/sj.bmt.1701646","journal-title":"Bone Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X1100900310","article-title":"Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis","volume":"9","author":"Kourelis TV","year":"2011","unstructured":"Kourelis TV, Moustakakis MN, Silk R, Pharm D, Boruchov A, Bilgrami SF. Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis. Eur J Inflamm. 2011, 9:289-92. 10.1177\/1721727X1100900310","journal-title":"Eur J Inflamm"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27012","article-title":"Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment","volume":"98","author":"Naka R","year":"2023","unstructured":"Naka R, Kondo T, Nishikubo M, et al.. Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment. Am J Hematol. 2023, 98:E251-4. 10.1002\/ajh.27012","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.732","article-title":"Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: a case report","volume":"4","author":"Akagi Y","year":"2023","unstructured":"Akagi Y, Yamashita Y, Kosako H, et al.. Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: a case report. EJHaem. 2023, 4:841-3. 10.1002\/jha2.732","journal-title":"EJHaem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182993","article-title":"Prognostic role of kidney disease in newly diagnosed acute myeloid leukemia under venetoclax-based low-intensity therapy","volume":"17","author":"Kr\u00fcger K","year":"2025","unstructured":"Kr\u00fcger K, Gabdoulline R, Wichmann M, et al.. Prognostic role of kidney disease in newly diagnosed acute myeloid leukemia under venetoclax-based low-intensity therapy. Cancers (Basel). 2025, 17:2993. 10.3390\/cancers17182993","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1897-4287-11-11","article-title":"Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease","volume":"11","author":"Labno-Kirszniok K","year":"2013","unstructured":"Labno-Kirszniok K, Nieszporek T, Wiecek A, Helbig G, Lubinski J. Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease. Hered Cancer Clin Pract. 2013, 11:11. 10.1186\/1897-4287-11-11","journal-title":"Hered Cancer Clin Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000845","article-title":"Clofarabine dosing in a patient with acute myeloid leukemia on intermittent hemodialysis: case report and review of the literature","volume":"39","author":"Benitez LL","year":"2017","unstructured":"Benitez LL, Gharibian K, Frame D, Mody R, Mora E. Clofarabine dosing in a patient with acute myeloid leukemia on intermittent hemodialysis: case report and review of the literature. J Pediatr Hematol Oncol. 2017, 39:481-4. 10.1097\/MPH.0000000000000845","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218801067","article-title":"Midostaurin administration in two hemodialysis patients","volume":"25","author":"Tollkuci E","year":"2019","unstructured":"Tollkuci E, Seddon A, Geswein L, Mulseh M. Midostaurin administration in two hemodialysis patients. J Oncol Pharm Pract. 2019, 25:1285-8. 10.1177\/1078155218801067","journal-title":"J Oncol Pharm Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220973259","article-title":"Gilteritinib administration in a hemodialysis patient","volume":"27","author":"Tollkuci E","year":"2021","unstructured":"Tollkuci E, Tran T, Myers R. Gilteritinib administration in a hemodialysis patient. J Oncol Pharm Pract. 2021, 27:1255-7. 10.1177\/1078155220973259","journal-title":"J Oncol Pharm Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2123230","article-title":"Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis","volume":"63","author":"Edahiro T","year":"2022","unstructured":"Edahiro T, Ureshino H, Chishaki R, et al.. Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis. Leuk Lymphoma. 2022, 63:3511-2. 10.1080\/10428194.2022.2123230","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1740357","article-title":"Case report: FIA plus venetoclax in a patient on hemodialysis","volume":"15","author":"Herstein JE","year":"2025","unstructured":"Herstein JE, Marx KR, Savoy JM, et al.. Case report: FIA plus venetoclax in a patient on hemodialysis. Front Oncol. 2025, 15:1740357. 10.3389\/fonc.2025.1740357","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02730-3","article-title":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","volume":"39","author":"Venditti A","year":"2025","unstructured":"Venditti A, Hou JZ, Fenaux P, et al.. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025, 39:2697-707. 10.1038\/s41375-025-02730-3","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo CD","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023, 401:2073-86. 10.1016\/S0140-6736(23)00108-3","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284185","article-title":"Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms","volume":"109","author":"Baranwal A","year":"2024","unstructured":"Baranwal A, Gurney M, Basmaci R, et al.. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024, 109:1779-91. 10.3324\/haematol.2023.284185","journal-title":"Haematologica"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.126","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik VI","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, et al.. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016, 30:2160-8. 10.1038\/leu.2016.126","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.008","article-title":"Hematopoietic stem cell transplantation in patients with chronic kidney disease","volume":"30","author":"Heher EC","year":"2010","unstructured":"Heher EC, Spitzer TR. Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol. 2010, 30:602-14. 10.1016\/j.semnephrol.2010.09.008","journal-title":"Semin Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/501523-management-of-acute-myeloid-leukemia-in-a-dialysis-dependent-patient-a-case-report-literature-review-and-therapeutic-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:18:22Z","timestamp":1781349502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/501523-management-of-acute-myeloid-leukemia-in-a-dialysis-dependent-patient-a-case-report-literature-review-and-therapeutic-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.110774","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}